Kirk Garratt, MD, medical director of the Center for Heart and Vascular Health, ChristianaCare, and a past president of SCAI, explains what this shortage means for interventional cardiologists.

Patients with higher levels of extravalvular cardiac damage prior to TAVR or SAVR face a higher risk of dying within two years, according to new findings presented at EuroPCR 2022 in Paris.

Imaging features were also examined as predictive time to resolution factors, with cortical thickness of the nodes being of particular interest.

Two separate sessions presented at SCAI 2022 focused on long-term outcomes associated with Shockwave Medical's IVL technology.

Vivasure Medical will use the funds to advance clinical development and attempt to secure regulatory approval of its vessel closure devices.

All-cause mortality after one year was 4.6% for the TAVR group and 6.6% for the SAVR group

Terry Bowers, MD, director of vascular medicine at Beaumont Hospital and national co-chair of the Pulmonary Embolism Research Collaborative (PERC), explains the trend toward creating pulmonary embolism (PE) response teams that include cardiology. 

A new study published in the Journal of the American College of Cardiology examined how a breast cancer survivor's eating schedule may impact their risk of cardiac events.